Transitional Cell Carcinoma in Dogs

Transitional cell carcinoma, often shortened to TCC and also called urothelial carcinoma, is the most common malignant tumor of the canine bladder. It develops from the cells that line the urinary tract and most often forms in the lower bladder near the trigone, the area where the ureters and urethra meet. That location matters because even a relatively small tumor can interfere with normal urine flow and cause signs that look very similar to a urinary tract infection. Because of that overlap, many dogs are first treated for infection before cancer is recognized.

Although bladder cancer is not one of the most common cancers overall in dogs, TCC is the urinary tract tumor vets see most often. It tends to be locally invasive, meaning it can grow into the bladder wall and nearby structures such as the urethra, prostate, or ureters. It can also spread to lymph nodes, lungs, and other sites. In many dogs, the goal of care is not cure but longer, more comfortable time with good quality of life. Early recognition helps your vet discuss realistic options, monitor for obstruction, and tailor care to your dog’s stage of disease and your family’s goals.

Some dogs are at higher risk than others. Scottish Terriers are especially overrepresented, and increased risk has also been reported in breeds such as West Highland White Terriers, Shetland Sheepdogs, Beagles, and some other terrier and herding breeds. Most affected dogs are older adults. Environmental exposures may also play a role in some cases, but TCC is usually considered a multifactorial disease rather than something caused by one single trigger.

Diagnosis usually starts with the same tests used for more common urinary problems. Your vet may recommend a physical exam, urinalysis, urine culture, bloodwork, and abdominal imaging. Ultrasound is especially helpful because it can show a mass, thickening of the bladder wall, involvement of the trigone, and changes in the kidneys or ureters. Chest imaging and lymph node evaluation may be added to look for spread.

Cancer-specific testing can help refine the picture. A bladder tumor antigen test may be used as a screening tool, but it is not specific and can be positive with infection, inflammation, or blood in the urine. A urine BRAF mutation assay is now widely used in dogs because many canine TCC cases carry this mutation, and the test can often detect tumor cells from a free-catch urine sample. A positive result can strongly support the diagnosis in the right clinical setting, but a negative result does not fully rule cancer out.

Definitive diagnosis is still based on identifying cancer cells, usually through cytology or biopsy when it can be done safely. That said, your vet may avoid traumatic sampling methods if there is concern about complications or tumor seeding. In some dogs, the diagnosis is made from a combination of history, imaging, urine testing, and response pattern rather than a full surgical biopsy. The best plan depends on tumor location, your dog’s stability, and whether the results would change treatment decisions.

There is no single proven cause of transitional cell carcinoma in dogs. Most cases are thought to result from a mix of genetic susceptibility, age-related risk, and environmental influences. TCC is seen most often in middle-aged to older dogs. Breed risk is one of the strongest known patterns, with Scottish Terriers standing out clearly. West Highland White Terriers, Shetland Sheepdogs, Beagles, and some other breeds also appear more likely to develop this cancer than the general dog population.

Researchers have also looked at environmental exposures. Some reports have linked lawn chemicals and herbicides, as well as secondhand smoke, with increased bladder cancer risk in dogs, though these links do not explain every case. Sex and neuter status may influence risk patterns in some studies, but they are not reliable enough to predict whether an individual dog will develop TCC. In practice, the most useful takeaway for pet parents is that persistent urinary signs in an older or high-risk dog deserve a thorough workup rather than repeated assumptions of infection alone.

A genetic mutation in the BRAF gene is found in many canine TCC cases, which is why urine-based BRAF testing can be helpful diagnostically. That mutation is important for detection, but it does not mean pet parents caused the cancer or could have prevented it. TCC is a complex disease, and even dogs with known risk factors may never develop it.

There is no guaranteed way to prevent transitional cell carcinoma in dogs. Because the disease appears to involve both inherited and environmental factors, prevention is mostly about lowering modifiable risks and catching problems early. If your dog is in a higher-risk breed, ask your vet how seriously to take recurring urinary signs and whether earlier imaging or urine-based cancer testing makes sense.

Reasonable prevention steps include avoiding unnecessary exposure to lawn chemicals and herbicides, reducing secondhand smoke exposure, and keeping up with routine wellness visits. These steps cannot promise protection, but they may reduce avoidable risk and improve early detection. Prompt follow-up matters too. If your dog is treated for a urinary tract infection and signs do not improve within the expected time, it is worth rechecking rather than repeating the same plan over and over.

For many families, the most practical form of prevention is vigilance. Blood in the urine, repeated urinary infections, or straining in an older dog should not be brushed off. Early workup does not always change whether the cancer can be cured, but it can change how quickly your vet can relieve obstruction, start treatment options, and protect quality of life.

The prognosis for dogs with TCC is guarded. This cancer is often not curable because of where it grows and because many tumors have already invaded nearby tissues or spread by the time they are found. Even so, many dogs can have meaningful time with good comfort when treatment is tailored to the stage of disease and monitored closely. Recovery in this setting usually means control of urinary signs and preservation of daily quality of life, not complete elimination of the cancer.

Expected survival varies widely depending on tumor location, whether there is obstruction, whether metastasis is present, and what treatment options are used. Dogs managed with medical therapy such as an NSAID alone may still gain symptom relief, while combination treatment with chemotherapy often offers longer control in appropriate cases. Dogs that develop urinary blockage may need urgent procedures such as stenting to restore urine flow. Those interventions can improve comfort and function, but they do not remove the underlying cancer.

At home, pet parents should watch for straining, reduced urine output, vomiting, black stools, appetite loss, weakness, or changes in thirst and urination, especially if the dog is taking an NSAID. Regular rechecks are important because your vet may need to adjust medications, monitor kidney values, or look for infection and progression. Quality-of-life conversations are a normal and important part of care for this disease.